The neurocognitive function change criteria after whole-brain radiation therapy for brain metastasis, in reference to health-related quality of life changes: a prospective observation study

Table 4 Percentage of patients divided into two groups (age, GPA, number of examinations, intracranial control at 4 months, Systematic therapies prior WBRT, Cytotoxic chemotherapy after WBRT, and Molecular targeted therapy after WBRT) with deterioration in NCF scores with 1.5 SD and HR-QOL scores at 4 months

Factors	Age group, %		p	GPA, %		p	No. of examinations, %		p	Intracranial control at 4 mos., %		p
Factors	< 65	≥65		4.0–2.0	1.5–0.0		3	2		Non-PD	PD
NCF:
TR	33	15	0.28	24	25	1.00	14	50	0.04*	8	62	< 0.01*
DR	38	15	0.16	18	33	0.31	14	58	< 0.01*	15	46	0.06
DRec	29	30	1.00	29	29	1.00	17	58	0.02*	23	39	0.45
COWAT	14	10	1.00	24	4	0.14	10	17	0.62	8	23	0.31
TMT-A	24	35	0.51	29	29	1.00	21	50	0.13	23	46	0.16
TMT-B	19	25	0.72	18	25	0.71	10	50	0.01*	4	54	< 0.01*
HR-QOL:
QLQ-C30;
Global Health Status	29	30	1.00	29	29	1.00	31	25	1.00	35	15	0.28
Functional scales	29	30	1.00	18	38	0.30	17	58	0.02*	19	46	0.13
Symptom scales	43	30	0.52	41	33	0.75	35	42	0.73	35	39	1.00
QLQ-BN20	33	40	0.75	41	33	0.75	35	42	0.73	35	31	1.00
Factors	Systemic therapies prior to WBRT, %			p	Cytotoxic chemotherapy after WBRT, %			p	Molecular targeted therapy after WBRT, %			p
Factors	No	Yes			No	Yes			No	Yes
NCF:
TR	13	32		0.27	27	21		0.73	18	32		0.47
DR	19	32		0.48	27	26		1.00	23	32		0.73
DRec	25	32		0.73	23	37		0.49	27	32		1.00
COWAT	13	12		1.00	14	11		1.00	18	5		0.35
TMT-A	31	28		1.00	18	42		0.17	36	21		0.33
TMT-B	6	32		0.07	23	21		1.00	18	26		0.71
HR-QOL:
QLQ-C30;
Global Health Status	31	28		1.00	36	21		0.33	36	21		0.33
Functional scales	19	36		0.31	23	37		0.49	32	26		0.74
Symptom scales	38	36		1.00	36	37		1.00	46	26		0.33
QLQ-BN20	38	36		1.00	32	42		0.53	55	16		0.02*

*p-value < 0.05
NCF neurocognitive function, TR Totall Recall domain of the Hopkins Verbal Learning Test-Revised (HVLT-R), DR Delayed Recall domain of the HVLT-R, DRec the Delayed Recognition domain of the HVLT-R, COWAT the Control Oral Word Association Test, TMT-A part A of the Trail-Making Test (TMT), TMT-B part B of the TMT, HR-QOL health-related quality of life, GPA Graded Prognosis Assessment, PD progressive disease. QLQ-C30 European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30. QLQ-BN20 European Organization for Research and Treatment of Cancer (EORTC) Brain Cancer Module

ISSN: 1471-2407